• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Aptamer Extends Collaboration with AstraZeneca

    Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark

    Reed-Lane Facility Virtual Tour
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Data Management Trends

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Aptamer Extends Collaboration with AstraZeneca
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Cytovance Biologics

    Adare Pharma Solutions

    Alcami

    Emergent BioSolutions

    Baxter BioPharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    Almac Group

    Adare Pharma Solutions

    PCI Pharma Services

    Emergent BioSolutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Expert's Opinion

    FDA’s Emergency Use Authorizations

    Aggressive Action Taken to Combat COVID-19

    FDA’s Emergency Use Authorizations
    Chad Landmon and Drew Hillier of Axinn, Veltrop & Harkrider LLP
    Related CONTENT
    • Novavax, Par Sterile Products Enter COVID-19 Vax Mfg. Pact
    • GRAM, J&J Enter COVID-19 Vax Manufacturing Pact
    • J&J Initiates Phase III ENSEMBLE Trial for COVID-19 Vax
    • Hovione to Support Manufacture of Remdesivir for COVID-19
    • ARCA Submits IND for AB201 in COVID-19
    Chad Landmon and Drew Hillier, Axinn, Veltrop & Harkrider LLP04.20.20
    As the world scrambles to combat the COVID-19 pandemic, the U.S. Food and Drug Administration (FDA) has been aggressively using its Emergency Use Authorization (EUA) process to facilitate getting medical products to healthcare workers and patients as quickly as possible. Following the declaration of a public health emergency by Health and Human Services (HHS) Secretary Alex Azar on February 4, 2020, FDA has issued nearly 70 EUAs for a variety of diagnostics, medical devices, and personal protective equipment directed to the coronavirus outbreak.  

    In diagnostics alone, FDA has worked with over 300 test developers interested in submitting EUAs, resulting in more than 30 EUAs. This unprecedented activity by FDA is likely to continue as the nation struggles to diagnose and treat those impacted by COVID-19. Companies who are developing treatments, diagnostics, personal protective equipment, and other medical products directed to the COVID-19 crisis should be mindful of FDA’s EUA process and consider obtaining an EUA when appropriate.  

    Summary of EUA Process
    Multiple legislative changes over the last decade to the Federal Food, Drug, and Cosmetic Act (FD&C Act) have granted the FDA Commissioner the ability to issue EUAs to authorize the marketing of unapproved medical products or unapproved uses of approved medical products to diagnose, treat, or prevent serious or life-threatening diseases or conditions. Before FDA can issue an EUA, however, an emergency declaration must first be made by the HHS Secretary, finding that one of our circumstances exist: 
     
    1.    a domestic emergency involving a heightened risk of attack with a chemical, biological, radiological, or nuclear (CBRN) agent;
    2.    a military emergency with a heightened risk of an attack with a CBRN agent on U.S. military forces;
    3.    a public health emergency affecting or with the significant potential to affect national security or the health and security of U.S. citizens living abroad, that involves a CBRN agent or related disease or condition; or
    4.    a material threat sufficient to affect national security or the health and security of U.S. citizens living abroad.

    Following the emergency declaration by the HHS Secretary, companies can request an EUA from FDA. According to FDA’s guidance on Emergency Use Authorization of Medical Products and Related Authorities (2017 Guidance), the following information should be included in an EUA request:

    •    Description of product and its intended use
    •    Description of the product’s FDA approval status
    •    The need for the product, including whether there are adequate, approved, and available alternatives
    •    Available safety and efficacy information, including, for example, any controlled clinical trials, in vitro testing, and/or clinical experience
    •    A discussion of risks and benefits, including: (a) measures taken to mitigate risk or optimize benefit; (b) limitations, uncertainty, and data gaps; (c) contraindications; and (d) actual and potential threats posed by CBRN agents that may be relevant.
    •    Information on chemistry, manufacturing and controls, and the sites of manufacture, including the current good manufacturing practices (CGMP) status of those sites
    •    Information on the quantity of product on-hand and surge manufacturing capabilities
    •    Information comparable to an FDA-approved package insert or instructions for use; drafts of Fact Sheets for health care professionals and recipients of the product; and a discussion of the feasibility of providing this information in an emergency  
    •    Information to support an extension of a label’s expiration date, if sought –and–
    •    Any right of reference to rely upon data submitted by others

    Given that FDA’s resources are taxed in responding to the emergency, companies seeking an EUA should reach out to FDA before filing a request to ensure that the proper information is being submitted and that any special issues identified by FDA can be resolved. If required by the emergency and if FDA has adequate information, FDA can issue an EUA within hours or days of a request.  

    FDA’s Aggressive COVID-19 EUA Activity
    FDA has been aggressively reviewing and approving EUAs as it tackles the COVID-19 health emergency. The first COVID-related EUA was issued on February 4, 2020 for the Center for Disease Control and Prevention’s (CDC) Real-Time Reverse Transcriptase Diagnostic Panel.  Since that time, FDA has issued approximately 35 additional EUAs to test kit manufacturers and commercial laboratories for various in vitro diagnostic products. On March 31, 2020, FDA announced that it would provide authorization for certified high-complexity labs to use molecular-based laboratory tests that had been developed by the lab seeking authorization. 

    Approximately 15 laboratories have been granted a letter including them under the March 31 EUA.  FDA’s EUAs have also extended to personal protective equipment, including three EUAs for respirators and one EUA for face shields.  Other EUAs include:  four EUAS for reprocessing medical devices that provide decontamination or sterilization; one EUA for ventilation equipment; two EUAs for extracorporeal blood purification devices; one EUA for a therapeutic product, chloroquine, and three EUAs for other medical devices such as pumps and diaphragm pacing therapy systems.

    Given the unprecedented nature of the coronavirus pandemic and its impact on our nation, including shortages of critical supplies and diagnostics, the life sciences industry has been actively ramping up production and pursuing EUAs like never before. In coordinating such efforts with FDA, needed products have been rushed into our healthcare system to stem the tide of COVID-19.  Only time will tell how effective these efforts will be.


    Chad Landmon chairs Axinn, Veltrop & Harkrider LLP’s Intellectual Property and Food and Drug Administration Practice Groups and focuses his practice on patent litigation and counseling and food and drug law, with an emphasis on pharmaceuticals, biologics, medical devices, and human tissue products. He maintains a particular focus on patent trial work and FDA litigation, having served as a first chair trial lawyer on multiple cases and having litigated over 50 cases during the past 10 years alone, many of which have included products with billions of dollars in annual sales.

    Drew Hillier is an attorney at Axinn, Veltrop & Harkrider LLP. His experience includes representing manufacturers of pharmaceutical, biologic, and medical-device products in patent litigation, as well as related commercial and regulatory matters. Drew graduated first in his class from the University of Connecticut School of Law, where he was editor-in-chief of the law review. He clerked for U.S. District Judge Michael P. Shea in the District of Connecticut.
    Related Searches
    • sterilization
    • production
    • biologics
    • marketing
    Suggested For You
    Novavax, Par Sterile Products Enter COVID-19 Vax Mfg. Pact Novavax, Par Sterile Products Enter COVID-19 Vax Mfg. Pact
    GRAM, J&J Enter COVID-19 Vax Manufacturing Pact GRAM, J&J Enter COVID-19 Vax Manufacturing Pact
    J&J Initiates Phase III ENSEMBLE Trial for COVID-19 Vax J&J Initiates Phase III ENSEMBLE Trial for COVID-19 Vax
    Hovione to Support Manufacture of Remdesivir for COVID-19 Hovione to Support Manufacture of Remdesivir for COVID-19
    ARCA Submits IND for AB201 in COVID-19 ARCA Submits IND for AB201 in COVID-19
    BioNTech to Acquire Novartis Mfg. Site for COVID-19 Vax Production BioNTech to Acquire Novartis Mfg. Site for COVID-19 Vax Production
    Pharma Supply Chain Logistics & Potential COVID-19 Vaccines Pharma Supply Chain Logistics & Potential COVID-19 Vaccines
    Lilly, Amgen Enter Antibody Mfg. Pact for COVID-19 Therapies Lilly, Amgen Enter Antibody Mfg. Pact for COVID-19 Therapies
    FDA Clears IND Application for Vaxart Oral COVID-19 Vaccine FDA Clears IND Application for Vaxart Oral COVID-19 Vaccine
    Valneva Partners with UK Government for COVID-19 Vaccine Valneva Partners with UK Government for COVID-19 Vaccine
    Valneva, Dynavax Enter COVID-19 Vax Supply Pact  Valneva, Dynavax Enter COVID-19 Vax Supply Pact
    Novavax, Serum Institute of India Enter COVID-19 Vax Mfg. Pact Novavax, Serum Institute of India Enter COVID-19 Vax Mfg. Pact
    BioNTech to Receive German Federal Ministry Funding for COVID-19 Vax BioNTech to Receive German Federal Ministry Funding for COVID-19 Vax
    AstraZeneca Temporarily Halts COVID-19 Vax Trials of AZD1222 AstraZeneca Temporarily Halts COVID-19 Vax Trials of AZD1222
    iBio Advances COVID-19 Vaccine Candidate iBio Advances COVID-19 Vaccine Candidate

    Related Expert's Opinion

    • Clinical Trials | Drug Development | Information Technology
      Virtual Clinical Trials: The Future of Dermatology Studies

      Virtual Clinical Trials: The Future of Dermatology Studies

      COVID-19 has created lasting impacts for clinical trials and a host of benefits have arisen from the adoption of virtual and hybrid models.
      Sonja VanWye, RN, MSN, Director, Dermatology Strategy, IQVIA Biotech 01.15.21

    • Clinical Trials | Drug Development
      The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs

      The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs

      Appropriate adaptive designs in early stages of development can accelerate timelines and reduce costs, and help focus on the most promising agents.
      Jürgen Hummel, MSc, Senior Director, Statistical Science, PPD, and Lead of PPD’s Adaptive Design Working Group 01.07.21

    • Drug Development | Industry News | Regulatory Affairs
      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to "normalcy".
      Chad Landmon, Michelle Divelbiss and Alex Alfano, Axinn, Veltrop & Harkrider LLP's Intellectual Property and Food and Drug Administration Practice Groups 01.05.21


    • Clinical Trials | Drug Development | Information Technology
      Advances in Intelligent Automation

      Advances in Intelligent Automation

      The future of medicine relies on further digital transformation and automation-enabling solutions to improve drug development and monitoring.
      Updesh Dosanjh, Practice Leader, Technology Solutions, IQVIA 12.14.20

    • Drug Development
      Navigating Uncertainty: Considerations for Life Sciences 2021

      Navigating Uncertainty: Considerations for Life Sciences 2021

      With vaccines against COVID-19 on the horizon, our focus is shifting to 2021 and the major issues life sciences companies face and reasons for optimism.
      Arda Ural , EY Americas Health Sciences and Wellness Industry Leader, Ernst & Young LLP 12.11.20

    • Drug Development
      New York City is Not Dead, Our Life Sciences Sector is Thriving

      New York City is Not Dead, Our Life Sciences Sector is Thriving

      Amid the COVID-19 pandemic, life sciences is booming in NYC!
      Sara Jane Demy, CEO & Founder, Demy-Colton 10.01.20


    • Clinical Trials | Drug Development
      How to Balance Internal and External Staff Within Outsourcing Models

      How to Balance Internal and External Staff Within Outsourcing Models

      Strategies to consider in flexed staffing models.
      John Barry, SVP, Consulting Practice and Chief Strategy Officer, PRA Health Sciences, SSD 09.22.20

    • Biologics, Proteins, Vaccines | Drug Development
      The Importance of Global Collaboration in the Fight Against COVID-19

      The Importance of Global Collaboration in the Fight Against COVID-19

      Industry continues to join forces to find new treatments for COVID-19.
      Dohyun Cho, Chief Operating Officer, Enzychem Lifesciences 09.08.20

    • Clinical Trials | Drug Development
      FDA Response to COVID-19

      FDA Response to COVID-19

      A Discussion on Protocol Amendments and Clinical Study Reports in Affected Ongoing Trials.
      Jack Modell, M.D., Vice President and Senior Medical Officer, Rho 09.03.20


    • Clinical Trials | Drug Development
      Beyond 2020: The Future of CROs

      Beyond 2020: The Future of CROs

      How will remote site access impact the CRO business?
      Ryan Jones, CEO, Florence Healthcare 08.21.20

    • Biologics, Proteins, Vaccines | Clinical Trials | Drug Development
      Global Biotech: Leading Health Care Innovation and How CROs Are Adapting to Meet Their Needs

      Global Biotech: Leading Health Care Innovation and How CROs Are Adapting to Meet Their Needs

      New models from CROs are enabling further biotech expansion
      Davide Garrisi, Biotech Portfolio Lead, PPD Biotech 08.20.20

    • Clinical Trials | Drug Development
      Pharma’s Imperative: Rethinking the FSP Outsourcing Paradigm

      Pharma’s Imperative: Rethinking the FSP Outsourcing Paradigm

      Evaluating outsourcing strategies amid a complex trial landscape to further enhance clinical operations.
      Michael D. Jones , Vice President of Clinical FSP Client Engagement, IQVIA 08.17.20


    • Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development
      Tackling Analytical Challenges in Gene Therapy

      Tackling Analytical Challenges in Gene Therapy

      Key considerations on how to navigate the field as a gene therapy developer.
      Khanh Ngo Courtney, Ph.D., Biologics Project Director, Avomeen 07.17.20

    • Drug Development | GMPs/GCPs | Information Technology | QA/QC
      Solving Compliance Challenges and Beyond with Natural Language Processing

      Solving Compliance Challenges and Beyond with Natural Language Processing

      Understanding new data sources and elevating compliance to drive innovation.
      Updesh Dosanjh, Practice Lead, IQVIA Vigilance Platform, IQVIA, Jane Reed, Head of Life Science Strategy, Linguamatics, an IQVIA company 06.16.20

    • Biologics, Proteins, Vaccines | Clinical Trials | Drug Development | Logistics
      The Importance of CAR-T Cell Therapy in Clinical Trials

      The Importance of CAR-T Cell Therapy in Clinical Trials

      The Industry’s Evolving, Maturing Focus
      Panteli Theocharous, Global Vice President, Cell and Gene Therapy Strategy Lead, PPD 05.26.20

    Trending
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • Reed-Lane Facility Virtual Tour
    Breaking News
    • AGC Biologics Expands Cell and Gene Facility in Italy
    • Celonic to Boost Cell & Gene Therapy Production
    • Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    • Aptamer Extends Collaboration with AstraZeneca
    • Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Thymoquinone Inhibits Viral Infection in In Vitro Settings, New Study Finds
    IFT Transitions 2021 Annual Event to Digital Experience
    NY Federal Judge Enters Permanent Injunction Against Dietary Supplement Manufacturer
    Coatings World

    Latest Breaking News From Coatings World

    Sherwin-Williams Announces Resignation of President and COO
    Ashland Completes Expansion and Relocation of Viatel Bioresorbable Polymers Manufacturing Facility
    Evonik Receives Sustainability Award from EcVadis
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Cretex CFO Announces Retirement
    New AI-Based Tool Developed for Coronary Artery Analysis, Intervention Planning
    First Reported Use of Pulse Biosciences' CellFX System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    AGC Biologics Expands Cell and Gene Facility in Italy
    Celonic to Boost Cell & Gene Therapy Production
    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Ulta Beauty Opens in Herald Square
    Elizabeth Arden Taps Sui He as Global Brand Ambassador
    Natura &Co Outperforms the Global Market in Q4 2020
    Happi

    Latest Breaking News From Happi

    What You're Reading on Happi.com
    Indie Beauty Innovators Wanted
    Cosmetic Chemists Seek Mentors
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Arjobex America welcomes Maggie Naberezny to sales team
    Henkel publishes 30th Sustainability Report
    Avery Dennison Smartrac launches new Circus Pro inlays
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FPInnovations Develops Biodegradable Mask
    Sani Professional Sanitizing and Disinfecting Products Approved by EPA
    Autefa Solutions Offers Fully Automated Line for Protective Mask Production
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Colfax Decides to Divide Its Businesses
    Stryker Corp.'s 2020 Sales Slip 3.6 Percent
    Bioventus Appoints Managing Director, China and Asia Pacific
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login